Stock Update (NYSE:MRK): Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes
September 17, 2014 at 09:31 AM EDT
[Business Wire] – Merck , known as MSD outside the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Merck’s investigational . . . → Read More: Stock Update (NYSE:MRK): Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes Similar Articles: Market Update (NYSE:LLY): New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies Company Update (NYSE:MRK): Merck Announces Third-Quarter 2014 Dividend Market Update: Merck & Co Inc (NYSE:MRK) – Merck to Hold Investor Briefing at Boston Research Facility